Our Investment Policy;
Our Vision: Building the Future of Bioelectrical Medicine
As AVB Biotechnology, our investment policy is focused on making the "Biomimetic Bioelectrical Modulation" technology, which we developed through the Dr Biolyse® platform, a global standard. Our investment strategy is built upon sustainable growth and the export of high value-added technology.
Our Strategic Focus Areas:
-
Global Regulatory Compliance: To ensure the highest level of registration of our technology in international medical device standards (MDR 2017/745) by completing its processes with the FDA and EMA in line with our 2026 goals.
-
Evidence-Based Growth: To transform our translational clinical data, whose success has been proven in different mammalian species (humans, pets, and farm animals), into academic and commercial value through advanced biostatistical methods.
-
Intellectual Property and Innovation: To create a "platform technology" ecosystem beyond hardware by protecting our bioelectrical code library and unique algorithms with global patents.
-
Diversified Market Access: To optimize cash flow and market share with products that have the potential for rapid commercialization in the fields of veterinary medicine and wearable health technologies, in addition to human medicine.
Commitment to Value Creation: While creating a paradigm shift in the healthcare sector with our non-pharmacological, side-effect-free, and innovative treatment protocols; we commit to creating long-term and sustainable value for our stakeholders through transparent management, scientific ethics, and disciplined capital management.